A Proof of Concept Study of Preemptive Treatment With Grazoprevir and Elbasvir for Donor HCV Positive to Recipient HCV Negative Kidney Transplant
Phase: PHASE4
Conditions: Renal Failure
Sponsor: Massachusetts General Hospital

Official title: A proof of concept study of 
preemptive treatment with grazoprevir and 
elbasvir for donor HCV positive to recipient 
HCV negative kidney transplant
NCT number: NCT02945150
Document date: 20 September 2017

Protocol: 2016P002051 
Compound: Elbasvir-grazoprevir    
Final 
Raymond Chung, MD
        Amendment 3: 20 September 2017 
Version 4.1 Dated: 20 September2017, inclusive of administrative amendment 1 
Partners Human Research Committee Detailed Protocol 
Title: A proof of concept study of preemptive treatment with grazoprevir and elbasvir for donor 
HCV positive to recipient HCV negative kidney transplant  
PI: Raymond Chung, MD 
PROTOCOL AMENDMENT SUMMARY OF CHANGES 
PROTOCOL AMENDMENT 3 
Original Protocol Date: 
11 January 2017 
Amendment 1 Date: 
07 February 2017 
Amendment 2 Date: 
12 June 2017 
Administrative 
Amendment 1 Date: 
13 July 2017 
Amendment 3 Date: 
20 September 2017 
Rationale 
Herein is a summary of the major changes made to the protocol 
dated 13 July 2017 and reflected in Amendment 2 dated 12 June 
2017: 
•
The donor inclusion and exclusion criteria have been
simplified.  Our goal was to ensure that the donor was high
quality. This is best done by setting an upper limit of the
KDPI (the kidney donor profile index) at 0.65.  We have
removed other criteria as they are actually captured in the
KDPI (which takes into account age, donation after cardiac
death, race, comorbidities, terminal creatinine).
•
We now allow recipients to be pre-dialysis as long as their
GFR is low enough at the screening visit
(<15mL/min/1.73m2) to suggest that dialysis is imminent
without a transplant.
•
We have extended the amount of accrued wait-time to 1095
days that a recipient may have if they are blood type B or O
(between 5-6years).  This is because these blood types have
substantially longer wait times than blood type A (between
3-5 years)

Protocol: 2016P002051 
Compound: Elbasvir-grazoprevir    
Final 
Raymond Chung, MD
        Amendment 3: 20 September 2017 
Version 4.1 Dated: 20 September2017, inclusive of administrative amendment 1 
•
We have modified the patient education session in response
to feedback from our Nephrology Patient Advisory
Committee to make the session more patient-friendly
•
We have increased the total number of subjects that can be
screened for this study from 30 to 40 because we have
found that so far many of the patients who are screened end
up being ineligible for transplant after they undergo
“transplant readiness evaluation” by the transplantation
unit. This is typically due to medical or psychiatric
comorbidities that were not detected at original listing for
transplant. Thus we expect to need to screen 40 patients to
find 11 that are able to undergo transplant
•
We now clarify that the “second visit” in the screening
period is either a phone or in-person visit per patient
request.  This allows the investigators an opportunity to
answer all questions and confirm patient eligibility, but
allows for flexibility in regards to where this visit takes
place, it can be done by phone if that is the patients
preference. This has been clarified in the informed consent
I.
Background and Significance
Currently in the United States, there are 133,925 patients waiting for organ transplants and 109,136 
of those await kidney transplants. In 2014, 17,105 kidney transplants took place, with only 13,299 
donors in total for that year.  Thus, there is a definite shortage of transplant viable organs in the 
U.S. In a survey of kidney donations between 1995 and 2009, of the 93,825 HCV-positive 
deceased donors (potentially 187,650 kidneys), over 50% were discarded. In Region 1, which 
encompasses the New England states and 4,050 patients on the national Waitlist, the discard rate 
of HCV-positive kidneys is 36% (data per New England Organ Bank). Furthermore, for the past 
decade, total kidney donors per year in the U.S. have reached a plateau of approximately 13,000 
donors each year,5 suggesting that kidney donations have reached a ceiling and that the kidney 
donor pool is  fixed at present levels.  
It is well established that there exists a significant survival benefit for patients with ESRD who 
receive a well-functioning kidney transplant, as compared to those remaining on dialysis and the 
kidney waitlist. Wait list time and duration of dialysis contribute greatly to outcomes for kidney 
transplants, with greater waiting and dialysis times associated with poorer post-transplant 

Protocol: 2016P002051 
Compound: Elbasvir-grazoprevir                                                                                                            Final 
Raymond Chung, MD                                                                              Amendment 3: 20 September 2017 
 
Version 4.1 Dated: 20 September2017, inclusive of administrative amendment 1 
 
outcomes. Therefore, it is of paramount importance and in accordance with the OPTN Final Rule 
that available resources are used efficiently;8 namely, that all potentially transplantable organs are 
recognized for their enormous value as scarce resources and should be utilized to their maximum 
potential for the maximum benefit (the principle of Utility).9  
Transplantation of HCV-positive donor kidneys to HCV-positive recipients has been performed 
for some twenty years with increasing evidence of long-term safety; some argue that it is an 
underutilized option.  One major advantage is a decrease in wait time and the potential to decrease 
waitlist mortality. However, a major concern with donor HCV-positive to HCV-positive recipients 
is that high viral loads contributing to accelerated allograft damage or an increased rate of post-
transplant diabetes. However, it is important to note that the above risks associated with 
transplantation of HCV-positive kidneys were all determined prior to the current era of HCV 
treatment. 
 
In contrast, traditional anti-HCV therapy depended on Interferon as the linchpin of single or 
combination therapy. Not only has Interferon been generally poorly tolerated, the risk of serious 
systemic side-effects has limited its use. When used in combination with transplant 
immunosuppression, acute HCV flare-ups have been reported including acute fulminant 
hepatitis.16 In addition, Interferon can elicit induction of class II antigen expression on renal 
tubules, which theoretically can lead to acute kidney rejection episodes (AR). Induction of AR and 
the requirement for a further increase in net immunosuppression to treat AR can cause an increase 
in viral replication, setting off a vicious cycle. This concern about AR has been one of the most 
formidable arguments against Interferon use in the immediate post-transplant setting. Finally, 
previous treatments with Interferon-based HCV regimens have been prone to complications, as 
enumerated above, even after a 6 month post-transplant waiting period. Overall, Interferon-based 
treatments have not been well tolerated and have produced underwhelming cure rates of 
approximately 50% (genotype 1).17 Because of this, it was generally recommended that patients 
with kidney transplants do not receive interferon-based HCV therapies.   
In the present era, direct-acting antiviral (DAA) therapies produce exceptionally high cure rates 
and are well tolerated.  DAAs have dramatically improved treatment options for patients with 
HCV. A recent study of kidney transplant recipients with HCV showed that 10 out of 11 patients 
receiving DAAs post-transplant were cured and treatment was well tolerated in all cases except 
for one.18 Modern DAAs offer exceedingly high cure rates (upwards of 95% for genotype 1), with 
minimal side-effects as compared to previous forms of treatment, especially those that were 
Interferon-based.19 
Grazoprevir, an inhibitor of the HCV NS3/4A protease and elbasvir, a NS5A inhibitor, in 
combination have been shown to be highly effective and well tolerated in patients with advanced 

Protocol: 2016P002051 
Compound: Elbasvir-grazoprevir                                                                                                            Final 
Raymond Chung, MD                                                                              Amendment 3: 20 September 2017 
 
Version 4.1 Dated: 20 September2017, inclusive of administrative amendment 1 
 
kidney failure. We believe this is the best choice for treatment in this population not only because 
it has been most extensively studied in renal failure, with 99% SVR12 (sustained virological 
response at 12 weeks), but also because of its minimal side effect profile, with only 2% of patients 
discontinuing the regimen due to adverse effects. This regimen is able to powerfully suppress viral 
load – with no on-treatment virologic breakthrough at 12 weeks of therapy19. Furthermore, this 
regimen has no significant interactions with commonly used immunosuppressant regimens.   
The optimal dosing of elbasvir and grazoprevir post transplant is determined based on data from 
the phase III C-EDGE trial, which assessed the efficacy and safety of elbasvir/grazoprevir for 12 
weeks in treatment-naïve adults (genotypes 1, 4, and 6). The sustained virologic response rate (cure 
rate) at 12 weeks (SVR12) was 92% in genotype 1A, 99% in genotype 1b (129/131) patients 
receiving 12 weeks of elbasvir/grazoprevir. When genotype 1A was evaluated more closely, it 
became clear that patients who had baseline high level resistance associated variant (RAVs) had 
lower rates of cure, this was overcome by adding weight-based ribavirin (1000 mg [<75 kg] to 
1200 mg [≥ 75 kg]) and extending the treatment course to 16 weeks. NS5A RAVs were identified 
at baseline in 12% (19/154) of genotype 1a-infected patients enrolled in the C-EDGE study of 
which 58% (11/19) achieved SVR12 compared to an SVR12 rate of 99% (133/135) in patients 
without these RAVs receiving 12 weeks of elbasvir/grazoprevir. It is now recommended that 
patients with high-level baseline RAVs prolong duration of treatment to 16 weeks and add 
ribavirin; this is based on extrapolation of data from the C-EDGE TE trial. In this phase III open-
label trial of elbasvir/grazoprevir that enrolled treatment-experienced patients, among 58 genotype 
1a patients who received 16 weeks of therapy with elbasvir/grazoprevir plus ribavirin, there were 
no virologic failures. Subsequent analysis of the elbasvir/grazoprevir phase II and III trials have 
demonstrated SVR12 rates of 100% (6 of 6 patients) in genotype 1 patients with pre-treatments 
NS5A RAVs treated with elbasvir/grazoprevir for 16/18 weeks plus ribavirin. Because of this we 
will perform NS5A resistance testing for any donor with genotype 1a infection to determine 
treatment duration and need for addition of ribavirin to treat the recipient. If baseline RAVs are 
present, i.e., polymorphisms at amino acid positions 28, 30, 31, or 93, treatment will be extended 
16 weeks with the addition of weight-based ribavirin to decrease the likelihood of transmission. 
In light of these recent advances in HCV therapy, we believe that elbasvir/ grazoprevir have the 
potential to play an important role in curtailing the current high discard rates for HCV-positive 
kidneys, an antiquated and wasteful practice, and one antithetical to the Final Rule.  We 
hypothesize that elbasvir/grazoprevir therapy could prevent or eliminate HCV infection that could 
occur after transplantation of a HCV-positive kidney into a HCV naïve host.  
If this approach proves successful, it has the potential to result not only in a large increase in the 
number of organs available in the kidney donor pool but also an overall increase in the quality of 
organ offers. The reason for this is that, unfortunately, many potential donors who are HCV 

Protocol: 2016P002051 
Compound: Elbasvir-grazoprevir                                                                                                            Final 
Raymond Chung, MD                                                                              Amendment 3: 20 September 2017 
 
Version 4.1 Dated: 20 September2017, inclusive of administrative amendment 1 
 
positive belong to a young demographic, aged 18 to 35 years, who are now caught up in the 
national epidemic of opioid and intravenous drug abuse, their deaths resulting from drug 
overdosing. Sadly, despite availability of curative HCV therapies, very few intravenous drug users 
are able to access this care, due to fragmented healthcare and payers unwilling to cover DAA 
medications in anyone with a positive drug screen. Thus, it is estimated that the HCV epidemic 
will continue to spread amongst young IVDU; currently there are over 2,000 new cases of HCV 
infection per year. Thus, we believe the pool of HCV-positive donors will continue to exist for 
decades. HCV-positive donor kidneys originating from this potential donor cohort, by virtue of 
their young age and statistical estimates of projected allograft performance after transplantation, 
are the most robust in the kidney donor pool. Demonstration that preemptive treatment of HCV 
can prevent HCV transmission would greatly expand the viable kidney donor pool and could result 
in a substantial reduction in long-term healthcare costs for patients being treated with dialysis who 
suffer from ESRD co-morbid complications. 
 
II. 
Specific Aims 
Primary Objective 
• Determine if the administration of grazoprevir and elbasvir (with or without ribavirin) for 
12-16 weeks after kidney transplantation prevents the spread of Hepatitis C virus (HCV) 
infection from a donor kidney with known Hepatitis C genotype 1 or 4 infection to a 
Hepatitis C negative recipient as evidenced by a negative HCV viral RNA at 12 weeks post 
treatment  
 
 
Secondary Objectives 
• Evaluate the safety and tolerability of grazoprevir and elbasvir (with or without ribavirin) 
in patients undergoing kidney transplantation 
• Determine the proportion of subjects with undetectable serum HCV RNA at study day 7, 
14, 28, 56, 84, 112, 168, 252, and 365 in kidney transplant recipients receiving grazoprevir 
and elbasvir (with or without ribavirin) in combination with a kidney transplant from an 
HCV infected donor. 
 

Protocol: 2016P002051 
Compound: Elbasvir-grazoprevir                                                                                                            Final 
Raymond Chung, MD                                                                              Amendment 3: 20 September 2017 
 
Version 4.1 Dated: 20 September2017, inclusive of administrative amendment 1 
 
III. 
Subject Selection 
The study will consist of 11 subjects to receive a transplant. 
This is a proof of concept, open-label single center study for the donation of HCV positive kidneys 
to HCV negative patients, with preemptive, interventional treatment to prevent HCV transmission 
upon transplantation. Patients will be selected based on having a significantly long waitlist time in 
order to maximize possible benefit from early transplantation.   
To ensure maximal benefit for the recipient, only high quality donor kidneys will be accepted; we 
will only accept those with low Kidney Donor Profile Index (KDPI) score. The KDPI is a 
numerical measure that combines ten dimensions of information about a donor, including clinical 
parameters and demographics, to express the quality of the donor kidneys relative to other donors. 
The KDPI is a cumulative percentage scale, based on a variety of donor factors used to compute 
the relative risk of graft failure after kidney transplant. Lower KDPI values are associated with 
increased donor quality; higher KDPI values are associated with lower donor quality. For instance, 
a donor with a KDPI of 80% has a higher expected risk of graft failure than 80% of all kidney 
donors recovered in the previous year. Kidneys with lower KDPI scores are associated with better 
post-transplant survival20. The chosen recipient may not otherwise have access to such high quality 
kidneys. 
1. Donor Inclusion/Exclusion Criteria 
1A. Donor Inclusion Criteria: 
a. Detectable HCV RNA, with HCV Genotype 1 or 4 infection – Genotyping will occur prior to 
transplantation. 
c. KDPI score is less than ≤ 0.650 
 
1B. Donor exclusion criteria 
a. Donor has been known to have previously received HCV treatment with a direct-acting antiviral 
agent 
b. Confirmed HIV  
c. Confirmed HBV positive (surface antigen or HBV DNA positive) 
d. Kidney anatomical damage or significant pathology noted during recovery 
e. Significant liver disease or signs of liver decompensation (splenomegaly, ascites) noted during 
recovery (advanced fibrosis or cirrhosis) 
f. Any standard contra-indication to donation noted in donor (significant malignancy, unusual 
infection) 
 
2. Recipient Inclusion/Exclusion Criteria 

Protocol: 2016P002051 
Compound: Elbasvir-grazoprevir                                                                                                            Final 
Raymond Chung, MD                                                                              Amendment 3: 20 September 2017 
 
Version 4.1 Dated: 20 September2017, inclusive of administrative amendment 1 
 
2a. Recipient Inclusion Criteria 
a. Recipient Age is 40-70 years old 
b. Met MGH transplant center criteria and already listed for isolated kidney transplant 
c. No available living kidney donor 
d. Has ≤ 730 days (2 years) of accrued transplant waiting time if blood type A and ≤ 1095 days of 
accrued transplant waiting time if blood type B or O. 
e. On chronic hemodialysis or peritoneal dialysis or has a glomerular filtration rate 
<15mL/min/1.73m2 at the time of screening 
f. Must agree to birth control. Women must agree to use birth control in accordance with 
Mycophenolate Risk Evaluation and Mitigation Strategy and at least one barrier method 
g. Weigh at least 50kg 
h. Serum ALT within normal limits with no history of liver disease 
i. Able to sign informed consent  
 
2b. Recipient Exclusion Criteria: 
a. AB blood type (given expected short waiting time on the transplant list) 
b. BMI > 35 
c. Any liver disease in recipient 
d. Pregnant or nursing (lactating) women 
e. Known allergy or intolerance to tacrolimus that would require administration of cyclosporine 
rather than tacrolimus given the known drug-drug interaction between cyclosporine and Zepatier™ 
f. Cardiomyopathy (LV ejection fraction < 50%)  
g. Albumin < 3g/dl or platelet count < 75 x 103/mL 
h. Positive crossmatch or positive donor specific antibodies 
i. HIV positive 
j. HCV RNA positive  
k. Hepatitis B surface antigen positive 
l. Any known liver disease or elevated liver transaminases 
m. Patients with primary focal segmental glomerulosclerosis (FSGS), FSGS recurring after 
previous transplant or disease process with increased risk of causing early graft failure as assessed 
by the transplant nephrologist and/or the investigator team 
n. Any contra-indication to kidney transplantation per our center protocol 
Patients will initially sign informed consent to be “waitlisted” for a HCV-positive kidney under 
this protocol.  We will include up to 3 patients per blood type, exclusive of AB blood type. At the 
time that the kidney transplant becomes available, the “waitlisted” patients will be contacted and 
again sign surgical informed consent for transplantation (standard of care).  

Protocol: 2016P002051 
Compound: Elbasvir-grazoprevir                                                                                                            Final 
Raymond Chung, MD                                                                              Amendment 3: 20 September 2017 
 
Version 4.1 Dated: 20 September2017, inclusive of administrative amendment 1 
 
Upon selection a patient will receive a preemptive treatment regimen of grazoprevir 100mg 
/elbasvir 50mg coformulated, given orally on the day of transplantation. Daily dosing will continue 
for 12-16 weeks post-transplantation. Dosing may vary depending on patient viral specifics:  
Genotype 1a: without high-level NS5A polymorphisms – grazoprevir/elbasvir x 12 weeks. With 
high level baseline NS5A polymorphisms - Grazoprevir/ elbasvir/ribavirin x 16 weeks 
Genotype 1b: grazoprevir/elbasvir x 12 weeks 
Genotype 4: grazoprevir/elbasvir x 12 weeks 
 
Rationale for age range of recipients: 
We are excluding young people because they are likely to have less comorbidity and have a high 
likelihood of surviving until transplant on the waitlist.  Rationale for excluding elderly > 70 years 
old is that this technique is possibly riskier in this population who may have more comorbidities, 
require more concomitant medications and more likely to have side effects. 
 
Full biochemical profiles of the patient will be performed at various stages throughout the study. 
On-Treatment safety monitoring schedule – (See standard of care post-transplant visit appendix) 
On-treatment safety labs include Baseline LFTs, CBC, comprehensive metabolic panel.  LFTs will 
be monitored week 2, 4, 8, 12, and 16 for any patient on 16 weeks of therapy. 
Standard of care at Partners includes confirming that female patients are not pregnant at the time 
of organ transplantation. Pregnant patients are not eligible for organ transplantation, regardless of 
their participation in the study.  We will review the subjects standard of care pregnancy test to 
confirm they are not pregnant at the time of transplant/study entry but will not repeat a study 
specific pregnancy test at the time of transplant. 
Study visits post-kidney transplantation will occur on days 1, 3, 7, 14, 28, 42, 56, 70, 84, 91, 95, 
112, 168, 252, 365  
Subjects who need to receive 16 weeks of therapy due to the presence of baseline RAVs will have 
an extra on-treatment visit at the end of therapy (Day 112) and will have their follow-up visits 
scheduled for 4 weeks post-treatment (day 140), 12 weeks post treatment (day 196), 24 weeks 
post-treatment (Day 280) and day 365.  They will also complete a 1 year follow-up visit.   
Targeted physical assessment, vital sign measurements, emergence of adverse events and 
concomitant medication usage will be assessed at scheduled visits and as needed at the time of any 
unscheduled contact during the 84 day (or 112 day) study period and/or the 365 day post-dosing 

Protocol: 2016P002051 
Compound: Elbasvir-grazoprevir                                                                                                            Final 
Raymond Chung, MD                                                                              Amendment 3: 20 September 2017 
 
Version 4.1 Dated: 20 September2017, inclusive of administrative amendment 1 
 
safety follow-up. For women of childbearing potential, a urine pregnancy test will be performed 
at all visits while taking the study medication.  A negative result will be required prior to continuing 
study treatment. 
40 subjects will be enrolled study wide.  We plan to enroll all 40 subjects at MGH. 
 
IV. 
Subject Enrollment 
This is a proof of concept, single center study for the donation of HCV positive kidneys to HCV 
negative patients, with preemptive, interventional treatment to prevent HCV transmission upon 
transplantation.  
Any patient interested in learning about HCV infection and this study will be invited to voluntarily 
attend a one-on-one information session (See Attachment) where they will be provided 
information about HCV, current treatments, current role in kidney transplantation, and have the 
opportunity to ask questions. After the session patients will be given the informed consent 
information to review at home.  If interested they will return for a screening visit (Visit 1). 
A study physician investigator will obtain informed consent. The consent form and protocol will 
be reviewed with the potential subject and any questions will be answered. The subject may be 
seen in a private area located on Renal Associates Clinic, 165 Cambridge St. Subjects will again 
have the option to take the consent form home with them for at least 24 hours to decide whether 
or not they wish to participate.   
 
In the case that an identified patient is a part of the medical practice of one of the investigators, 
this patient will have an information session and screening visit conducted by a different physician 
investigator.  
Ability to provide informed consent will be determined by the study investigator in discussion 
with the subjects treating physician. Subjects who cannot provide informed consent due to their 
clinical presentation will not be included. Surrogate consent will not be allowed in this study. 
 
V. 
Study Procedures 
Laboratory analyses, adverse effects, vital signs, and concomitant medications will be monitored 
at screening and all subsequent study visits through the end of the study.  Serum pregnancy tests 
(for all females of childbearing potential) will be conducted at screening.  At MGH, a serum 
pregnancy test will be done immediately prior to transplantation for all women of reproductive age 
as a standard of care. 

Protocol: 2016P002051 
Compound: Elbasvir-grazoprevir                                                                                                            Final 
Raymond Chung, MD                                                                              Amendment 3: 20 September 2017 
 
Version 4.1 Dated: 20 September2017, inclusive of administrative amendment 1 
 
 
In the case of isolated HBV cAb we will first ensure that this finding is worked up fully before 
transplant listing.  Ordinary protocol is to monitor HBV DNA levels and this will be done, periodic 
HBV DNA post transplant per MGH kidney transplant standard of care and treatment started if 
DNA becomes positive.  Patients with isolated HBV cAB positive will still be included and will 
follow standard of care monitoring. 
 
The screening visit will take place within an estimated 6 months prior to kidney transplantation. 
 
Day 0 of this study represents the day of kidney transplantation and study drugs will begin on this 
day.  
 
Each subject will receive their study drugs (elbasvir 50mg and grazoprevir 100mg) daily for the 
duration of the study period.   
 
With the prior approval of the patients treating MD team, statin use will be suspended while on 
elbasvir/grazoprevir and will be started no sooner than 2 weeks after treatment discontinuation. If 
there is an urgent need for statin use during the administration of grazoprevir/elbasvir as 
determined by treating physicians then we will request that pravastatin or pitavastatin be used as 
there is no clinically significant interactions of these two statins with Zepatier™.  
 
Genotyping and Resistance-associated variant (RAV) testing will take place on the kidney 
donor’s serum at the time of organ procurement. Rapid Genotyping is part of our allocation 
algorithm and is a component of the pre-transplant donor testing prior to organ implantation. 
This testing will be conducted in collaboration with the New England Organ Bank.  Only 
patients with genotype 1 (1a or 1b) or genotype 4 are eligible to be transplanted. NS5A RAVs 
appear to have impact on treatment response with regimens that include an NS5A inhibitor and 
this impact occurs primarily with genotype 1a. NS5A variants with potential clinical 
significance include variant amino acids at positive 28, 30, 31, and 93 (HCVguidelines.org, 
accessed September 6, 2016). It is expected that 12% of donors with genotype 1A infection will 
have high level baseline RAVs. Any patient who receives a kidney transplant from a donor 
with donor with high level RAVs will have weight-based ribavirin (daily dose 1000 mg for 
those <75 kg and 1200 mg for those ≥75 kg) added to their regimen and the treatment course 
will be extended to a total of 16 weeks. Should any new RAVs be discovered during the 
duration of this study we will follow the most up to date recommendations based on 
HCVguidelines.org.  
RAV testing will be performed on donor serum. Because this test cannot be done rapidly, it will 
be performed from serum taken at the time of organ procurement. Transplant of an organ will 

Protocol: 2016P002051 
Compound: Elbasvir-grazoprevir                                                                                                            Final 
Raymond Chung, MD                                                                              Amendment 3: 20 September 2017 
 
Version 4.1 Dated: 20 September2017, inclusive of administrative amendment 1 
 
take place without knowledge of RAV status.  The RAV testing is necessary ONLY for patients 
with genotype 1A and results should return within 7-13 days and at that point, if needed based on 
the finding of high level RAVs, ribavirin will be added (by day 14 post transplant) and the 
patient will be informed that their planned treatment course will be extended to 16 weeks.  
NS5A polymorphism testing will be a send-out test to Monogram Biosciences (South San 
Francisco, CA) via LabCorp. This is a CLIA-Approved lab. Results expected in 7-13 days with 
initiation of ribavirin if needed by day 14. 
If worst case scenario arises and the patient is intolerant to ribavirin, published studies still show 
that the cure rate of HCV is still reasonable in those with high level RAVs who receive just elbasvir 
and grazoprevir for a traditional course. Dose reductions for ribavirin related adverse events would 
be given per the package insert recommendations as outlined in section 2.3 and 2.4 of the attached 
document. 
 
Assessments (also see Appendix 1) 
Pre-screening workup 
Informed consent for evaluation 
Completed education session with RN and MD 
Complete medical history  
Complete physical exam 
Laboratory screening (HCV, HIV HBV testing, Comprehensive Metabolic panel, LFTs, CBC with 
differential, Coagulation tests) 
Blood sample for storage 
ECG monitoring 
Quality of life assessment (SF36) 
Phone call from study physician prior to transplant 
 
Baseline testing (at transplant, day 0) 
 
HCV RNA, Comprehensive Metabolic panel, LFTs, CBC with differential, Coagulation tests, 
blood sample for storage. 
Review of concomitant meds 
 
Week 1 (Visits on Days 1, 3, 7) -  
Window for on treatment study visits will be +/- 3 days  
HCV RNA, Comprehensive Metabolic panel, LFTs, CBC with differential 
Blood sample for storage 
Adverse event reporting 

Protocol: 2016P002051 
Compound: Elbasvir-grazoprevir                                                                                                            Final 
Raymond Chung, MD                                                                              Amendment 3: 20 September 2017 
 
Version 4.1 Dated: 20 September2017, inclusive of administrative amendment 1 
 
Standard of care post-transplant visit (see transplant protocol) 
ECG monitoring 
Review of concomitant meds 
 
Week 2 (Day 14) 
Window for on treatment study visits will be +/- 3 days  
HCV RNA, Comprehensive Metabolic panel, LFTs, CBC with differential 
Blood sample for storage 
Adverse event reporting 
Standard of care post-transplant visit (see transplant protocol) 
Review of concomitant meds 
 
Week 4 (Day 28) 
Window for on treatment study visits will be +/- 3 days  
 
HCV RNA, Comprehensive Metabolic panel, LFTs, CBC with differential 
Blood sample for storage 
Adverse event reporting 
Standard of care post-transplant visit 
ECG monitoring 
Review of concomitant meds 
 
Week 6 (Day 42) 
Window for on treatment study visits will be +/- 3 days  
 
HCV RNA, Comprehensive Metabolic panel, LFTs, CBC with differential 
Blood sample for storage 
Adverse event reporting 
Standard of care post-transplant visit – (see transplant protocol) 
Review of concomitant meds 
 
Week 8 (Day 56) 
Window for on treatment study visits will be +/- 3 days  
 
HCV RNA, Comprehensive Metabolic panel, LFTs, CBC with differential 

Protocol: 2016P002051 
Compound: Elbasvir-grazoprevir                                                                                                            Final 
Raymond Chung, MD                                                                              Amendment 3: 20 September 2017 
 
Version 4.1 Dated: 20 September2017, inclusive of administrative amendment 1 
 
Blood sample for storage 
Adverse event reporting 
Standard of care post-transplant visit – (see transplant protocol) 
Review of concomitant meds 
Quality of life assessment (SF36) 
 
Week 10 (Day 70) 
Window for on treatment study visits will be +/- 3 days  
 
HCV RNA, Comprehensive Metabolic panel, LFTs, CBC with differential 
Blood sample for storage 
Adverse event reporting 
Standard of care post-transplant visit – (see protocol) 
Review of concomitant meds 
 
Week 12 ( Day 84) 
Window for on treatment study visits will be +/- 3 days  
 
HCV RNA, Comprehensive Metabolic panel, LFTs, CBC with differential, Coagulation testing 
Blood sample for storage 
Adverse event reporting 
Standard of care post-transplant visit – (see protocol) 
ECG monitoring 
Review of concomitant meds 
 
Week 13 (Day 91 and Day 95) Laboratory Only Visit (may be done off-site) 
 
Kidney function tests  
Tacrolimus level monitoring 
 
Week 16 (if needed based on baseline RAV testing of donor) (Day 112) 
Window for on treatment study visits will be +/- 3 days and +/- 5 for post treatment visits. 
 
HCV RNA, Comprehensive Metabolic panel, LFTs, CBC with differential 
Blood sample for storage 
Adverse event reporting 

Protocol: 2016P002051 
Compound: Elbasvir-grazoprevir                                                                                                            Final 
Raymond Chung, MD                                                                              Amendment 3: 20 September 2017 
 
Version 4.1 Dated: 20 September2017, inclusive of administrative amendment 1 
 
Standard of care post-transplant visit – (see protocol) 
ECG monitoring 
Review of concomitant meds 
 
SVR 4 Visit (Day 112, or Day 140 if on 16 week course) 
Window for study visits will be +/- 5 days for post treatment visits. 
 
HCV RNA, Comprehensive Metabolic panel, LFTs, CBC with differential  
Blood sample for storage 
Adverse event reporting 
Standard of care post-transplant visit – (see protocol) 
Review of concomitant meds 
 
SVR12 Visit (Day 168 or Day 196 if on 16 week course) 
Window for study visits will be +/- 5 days for post treatment visits. 
 
HCV RNA, Comprehensive Metabolic panel, LFTs, CBC with differential 
Blood sample for storage 
Review of concomitant meds 
Quality of life assessments (SF36) 
 
SVR 24 Visit (Day 252 or Day 280 if on 16 week course) 
Window for study visits will be +/- 5 days for post treatment visits. 
 
HCV RNA, Comprehensive Metabolic panel, LFTs, CBC with differential 
Blood sample for storage 
Review of concomitant meds 
 
1 year visit (Day 365) 
Window for study visits will be +/- 5 days for post treatment visits. 
 
HCV RNA, Comprehensive Metabolic panel, LFTs, CBC with differential,Coagulation tests 
Blood sample for storage 
Review of concomitant meds 
Quality of Life assessment (SF36) 

Protocol: 2016P002051 
Compound: Elbasvir-grazoprevir                                                                                                            Final 
Raymond Chung, MD                                                                              Amendment 3: 20 September 2017 
 
Version 4.1 Dated: 20 September2017, inclusive of administrative amendment 1 
 
 
Plan For Intensive Monitoring 
Three situations will prompt beginning an intensive monitoring study visit schedule. 
1. Medical need to begin a medication with known interaction with Zepatier™ 
2. Need to begin a transplant medication that has not been studied in combination with 
Zepatier™ 
3. Any patient experiencing a study drug related side-effect 
If, for example, an azole is needed, tacro levels will be monitored twice weekly until stability is 
established, as is clinically indicated whenever an azole is added to a tacrolimus level. Co-
administration with mTOR inhibitors has not been studied to our knowledge. We would adhere to 
the best standard-of-care currently practiced, which entails frequent monitoring of drug levels on 
this or any class of immunosuppressant, in addition to monitoring eGFR. Any patient with 
unforeseen need for a medication with a known interaction with elbasvir/grazoprevir (including 
azoles) would be subjected to a change in study visit schedule and would come weekly for the 
duration of Zepatier™ treatment.   
 
Plan For Management of Patient Requesting Early Termination From the Study 
If a subject decides to stop taking part in the study after the treatment period for any reason, we 
will ask them to make a final study visit, called the Early Termination Visit.  They will need to 
return all unused study drug at this visit.  The final study visit will take about 30 minutes.  At this 
visit, we will: 
• 
Give a physical exam and check on any new symptoms or new medications since their last 
visit 
• 
Measure their weight 
• 
Record their vital signs 
• 
Draw some blood samples to measure if there is any Hep C virus in their blood, and the 
amount of anti-rejection medicine in their body, and for routine lab tests 
If the patient decides to stop taking part in the study during Zepatier™ treatment, we have the 
following plan in place: 
Although we would attempt to avoid this by fully informing the subject ahead of protocol 
participation, including an information session, detailing the immediate and downstream risks 
inherent in potential HCV transmission if medication is stopped, should a patient request 
study drug termination:  We would immediately convene an intervention group that included 
the following to make sure that all attempts are made to address any potential issues that are 
leading to patients wanting to drop out of the study. 
1. A study MD investigator 

Protocol: 2016P002051 
Compound: Elbasvir-grazoprevir                                                                                                            Final 
Raymond Chung, MD                                                                              Amendment 3: 20 September 2017 
 
Version 4.1 Dated: 20 September2017, inclusive of administrative amendment 1 
 
2. A Non-study related treating MD (ie the patients primary MD or Nephrologist) 
3. The patients family member or close personal friend 
4. A patients advocate/social worker 
Finally, if the worst-case scenario was to play out and they were to get HCV, we now know that 
HCV is a treatable disease, no longer a death sentence. If transmission occurred, we would re-
group and determine a successful therapeutic strategy to eradicate HCV. Although complications 
of HCV take decades to develop, we would help the patient become quickly connected to 
appropriate HCV care providers. 
In the event of a possible HCV Seroconversion. We will pair sofosbuvir and ribavirin with 
elbasvir and grazoprevir for a repeat course. With established HCV infection, we would apply to 
the insurer for coverage of course of antiviral therapy.  
Sofosbuvir use has not been well studied with eGFR < 30. At this point the patient would be > 
12 weeks from transplant and the incidence of ongoing delayed graft function is low making it 
unlikely that the patients would have persistent severe renal impairment (eGFR < 30). Chances 
of eGFR < 30 at 12 weeks given the excellent kidney quality being selected for this study (see 
inclusion criteria) is < 10% at 3mo mark. Additionally, there are other regimens that are not 
renally excreted that could be used for this population soon available on the market (by 2017) 
that could be applied for through their insurance.    
Plan for Patients That Develop a HCV Infection 
The primary investigator, Dr. Chung, will advocate on behalf of the subject using his expertise to 
advise the appropriate salvage therapy. Every effort will be made with the insurer first and then 
the drug companies to secure effective treatment in this situation. 
Plan for Waitlisted Patients After Study Completion 
If the enrollment for this study closes (i.e. 11 patients have been participated and received a 
transplant), then patients will be notified that this protocol is over by phone call.  We expect that 
with positive results from this study and others that there would be new larger studies of this 
technique (treating post transplant) with this and other anti-HCV regimens. 
 
 
VI. 
Biostatistical Analysis 
Variables/Time Points of Interest 
The primary variable of interest will be HCV RNA at the multiple time-points assessed during and 
after treatment.  

Protocol: 2016P002051 
Compound: Elbasvir-grazoprevir                                                                                                            Final 
Raymond Chung, MD                                                                              Amendment 3: 20 September 2017 
 
Version 4.1 Dated: 20 September2017, inclusive of administrative amendment 1 
 
 
The primary efficacy outcome “Prevention of HCV Transmission” will be determined by a 
negative HCV RNA  
 
The safety outcomes include summation of treatment related adverse events and transplant 
rejection or patient mortality. On treatment eGFR, proteinuria, hemoglobin, and liver function tests 
will be summarized to assess safety. 
 
Statistical Methods 
The first case will be described as a case report.  Should HCV transmission be prevented with this 
protocol then a cohort of 10 patients will be recruited. 
 
Patient characteristics for the follow-up cohort (N=10) will be presented with summary statistics 
for baseline demographics, clinical variables.  The SVR12 rate will be presented and 95% CI 
constructed with the exact test.  Mean and standard deviation for on-treatment laboratory values 
will be presented to analyze safety. 
 
Power/Sample Size: 
This is a pilot study.  The first patient will be enrolled and complete the protocol as a proof of 
concept. Provided transmission does not occur, N=10 more patients will be enrolled in this pilot 
study.  
 
VII. 
Risks and Discomforts 
Psychological risk 
 
Participation in research may result in undesired changes in thought process or emotion (episodes 
of depression, stress, guilt). Patients may experience discomfort when being asked questions about 
their medical history that they deem to be private. 
 
Risks related to transplantation with a HCV kidney 
 
Liver problems 
 
It is possible that Zepatier™, which cured > 95% with HCV, will not work as well after a kidney 
transplant as it has worked in patients who did not have a transplant. It is also possible that after 
kidney transplant, a HCV infection could cause serious health problems, including liver failure or 
death. HCV can cause a rare but severe liver inflammation in the first few weeks to months after 
transplant. In the short term, infection with HCV can cause a flu-like illness that includes fatigue, 
nausea, fever, abdominal pain, vomiting, joint pain, and yellowing of the skin (jaundice). Although 

Protocol: 2016P002051 
Compound: Elbasvir-grazoprevir                                                                                                            Final 
Raymond Chung, MD                                                                              Amendment 3: 20 September 2017 
 
Version 4.1 Dated: 20 September2017, inclusive of administrative amendment 1 
 
it is very rare, infection with HCV can cause severe inflammation of the liver or even liver failure, 
including a condition called fibrosing cholestatic hepatitis. The risk of this complication in patients 
without HCV who receive a transplant from a donor with HCV is unknown. This complication can 
be treated and cured in some cases with the HCV medications that the study will be providing. 
 
Cirrhosis of the liver can cause someone to experience leg swelling, yellow skin, skin itching, 
abdominal bleeding, shortness of breath, and the abdomen to fill with fluid (ascites). Liver failure 
can also cause death. Based on the limited data available, it would be extremely rare for someone in 
the study to experience liver failure in the first few months after transplantation because the study 
will be giving HCV treatment right away. However, because liver failure is possible, the study is 
only enrolling individuals in this study who would potentially be eligible to receive a liver transplant 
if they developed liver failure after a kidney transplant, which is why the screening process for this 
study requires that you have good heart function on the echocardiogram you underwent as a part of 
your transplant workup.  
 
If the patient develops HCV infection despite getting Zepatier™, and it cannot be cured with the 2nd 
line treatment given through this trial, over time, there may be continued inflammation and scarring 
of the liver that over many years (10-30) can lead to cirrhosis. If HCV causes cirrhosis, the patient 
is at increased risk of developing liver cancer, liver failure requiring a liver transplant, or death.  
 
Additional risks of HCV:  
HCV can cause other types of inflammation in the body, such as arthritis, rash, anemia, nerve pain 
and inflammation damage to your kidney transplant. These problems are rare, and affect < 2% of 
people who have HCV. These problems should respond to effective treatment for the HCV. 
 
Risks of the test used to determine the HCV virus genotype 
The study intends only to transplant organs from patients with HCV – genotype 1 or 4. There is less 
than a 1% chance that the test the study uses to identify the virus might not be accurate. If the test 
gives the wrong result and the patient receives a kidney that has a different genotype of virus in it, 
the patient will still be treated, but the chances of cure may be lower.  
 
Risks Related to Study Medications 
 
Risks of Zepatier™ 
Elbasvir/grazoprevir is an FDA approved regimen for treating HCV infection and thousands of 
patients have received this medication. Based on the type of HCV the donor was infected with, 
some patients will also need to take ribavirin.  Ribavirin is also approved by the FDA to treat HCV 
infection. 
 
In patients receiving elbasvir/grazoprevir for 12 weeks the most common side effects were fatigue, 
headache and nausea (occurring in approximately 1 in 10 patients). Only 1 in 100 patients had side 
effects so severe that had to stop treatment due to a side effect. 
 

Protocol: 2016P002051 
Compound: Elbasvir-grazoprevir                                                                                                            Final 
Raymond Chung, MD                                                                              Amendment 3: 20 September 2017 
 
Version 4.1 Dated: 20 September2017, inclusive of administrative amendment 1 
 
In patients treated with elbasvir/grazoprevir plus ribavirin for 16 weeks the most commons side 
effect was anemia (8 in 100) and headache (6 in 100). Three in 100 patients had to stop treatment 
due to side effects.  
 
The safety and tolerability of Zepatier™ after kidney transplantation have also not been studied. It 
is possible that taking immunosuppressant medications needed after kidney transplant may change 
the effectiveness or side effects of Zepatier™.  
 
This drug regimen was chosen as first-line therapy for this study rather than other approved agents 
because this investigational agent is unique in that it can be safely used in patients with abnormal 
kidney function. The cure rates for patients with known HCV and chronic kidney disease (including 
being on dialysis) are similar to rates of patients without kidney disease. As a result, if kidney 
function has not fully recovered when treatment is initiated after transplant, the investigational 
agents can be safely given to you even if it takes some time for the kidney transplant to start 
working properly. 
 
Risks of Ribavirin (Applies only to the minority with genotype 1a and positive resistance testing) 
 
Ribavirin has been marketed for the treatment of HCV infection administered in combination with 
other HCV drugs (ribavirin is not effective against HCV infection when given by itself). Side 
effects which may be experienced with RBV include: Nausea, anorexia, vomiting, diarrhea, 
dyspepsia, abdominal pain, insomnia and rash. Hemolytic anemia can occur. The breakdown of 
red cells may lead to increased levels of bilirubin, and uric acid. The hemolytic anemia may cause 
worsening of heart disease which may lead to heart attacks and, sometimes, death.  
 
A small percentage of patients may need ribavirin (expected to be 6.7% of all study participants, 
since 67% expected to be genotype 1A and 33% expected to be genotype 1B and only 10% of 
genotype 1A recipients have RAVs requiring additiona of RBV). In this small percentage, there is 
a risk of worsening anemia, particularly those with delayed graft function. Erythropoetin 
stimulating agents will be continued in the post-transplant period if needed. In general, anemia in 
the setting of delayed graft function (DGF) does not have to be treated in the short term. Because 
the anticipated graft function in this cohort of donors is expected to be quite robust, we would not 
expect DGF to endure longer than one to two weeks post-operatively.  
 
Significant birth defects if pregnancy occurs while taking the drug or pregnancy occurs up to 6 
months after taking the drug.  
 
Risk of allergic reaction  

Protocol: 2016P002051 
Compound: Elbasvir-grazoprevir                                                                                                            Final 
Raymond Chung, MD                                                                              Amendment 3: 20 September 2017 
 
Version 4.1 Dated: 20 September2017, inclusive of administrative amendment 1 
 
As with any drug, an allergic reaction can occur. Allergic reactions can be mild or serious, and can 
even result in death in some cases. Common symptoms of an allergic reaction are rash, itching, 
skin problems, swelling of the face and throat, or trouble breathing.  
 
Risk of developing Resistance of the virus to other HCV treatments 
If Zepatier™ does not prevent HCV infection, there is a risk that the virus will develop resistance to 
Zepatier™ and other similar drugs. This could limit treatment options for the patient in the future.  
 
Risks Related to Study Procedures 
 
Risk of Stored Samples 
 
Storing research samples can potentially become a confidentiality risk. If future studies involve 
genetic testing, then there is a chance that this genetic information could get out.  
 
Risks of Blood Draws 
 
The patient may have a bruise (a black-and-blue mark) or pain where researchers take the blood 
samples. There is also a small risk of feeling lightheaded, fainting, or infection.  
   
 
Risks to an Embryo or Fetus, or to a Breastfeeding Infant 
 
Because the effect, if any, of Zepatier™ on an embryo or fetus is not known, the patient may not 
participate in this study if they are pregnant, breastfeeding, or planning to become pregnant.  The 
patient must agree not to get pregnant during the study and for 6 months after the completion of 
the study.   
 
VIII. Potential Benefits 
 
Participants may receive a high quality kidney transplant because they are enrolled in this study. 
They may wait for a much shorter period of time than they otherwise would have if they had not 
been a part of the research study. It is possible that patients will not get an HCV infection even 
though the kidney donor was known to have an HCV infection.  
A kidney that would have gone to waste would be used to prolong the life of an individual. This 
procedure could also eliminate costs of dialysis for a recipient and the healthcare system. The study 
overall could serve as a proof of concept that would end up greatly reducing healthcare costs due 
to extended wait-times and complications on dialysis. It could also increase the number of viable 
kidneys for transplant and greatly reduce the HCV-positive kidney discard rate. 

Protocol: 2016P002051 
Compound: Elbasvir-grazoprevir                                                                                                            Final 
Raymond Chung, MD                                                                              Amendment 3: 20 September 2017 
 
Version 4.1 Dated: 20 September2017, inclusive of administrative amendment 1 
 
 
IX. 
Monitoring and Quality Assurance 
An independent data safety monitoring board (DSMB) will not be used in this study as it is an 
open label study, will have low enrollment (11 subjects total) and will only take place at 1 sites  
 
Once a patient is enrolled, Dr. Williams, Dr. Chung, Dr. Sise, Dr. Wojiechowski, and Dr. Elias 
will meet in person every three months to review any safety concerns. More frequent meetings 
will occur if needed. Dr. Chung and Dr. Sise will be regularly monitoring the study documents for 
accuracy and meeting with study staff to review the status of the study. Dr. Chung will ultimately 
be responsible for protecting the rights, safety and welfare of all subjects enrolled in this study. In 
the case of Dr. Chung’s absence, monitoring responsibilities will be delegated to one of the sub-
investigators listed on the 1572 as well as the IRB protocol application. 
 
Adverse events will be thoroughly assessed at each treatment visit. Adverse events will be reported 
to the HRC as per current guidelines. We plan to comply with the reporting of any IND safety 
reports or any other federal regulations. The study coordinator will work with the physician 
investigators to process the report of these events as they happen. 
 
Adverse events and unanticipated problems involving risks to subjects or others will be reported 
to the PHRC in accordance with PHRC adverse event and unanticipated problems reporting 
guidelines. 
 
Dr. Chung will ensure that all adverse events are reported according to the PHRC guidelines. 
 
Dr. Chung and the study staff will meet monthly to review the accuracy and completeness of case 
report form entries, source documents, informed consent, and all regulatory documents. 
 
 
X. 
References 
 
1. Kidney Data: accessed 11/3/15: http://optn.transplant.hrsa.gov/converge/data/ 
2. Ibid. 
3. Kucirka L.M., Singer A.L., Ros R.L., Montgomery R.A., Dagher N.N., Segev D.L., 
Underutilization of Hepatitis C-positive Kidneys for Hepatitis C-positive Recipients, Am 
J Transplant. 2010 May; 10(5):1238-46.NEOB: annual report 2014. 
4. Kidney Data: accessed 11/3/15: http://optn.transplant.hrsa.gov/converge/data/ 

Protocol: 2016P002051 
Compound: Elbasvir-grazoprevir                                                                                                            Final 
Raymond Chung, MD                                                                              Amendment 3: 20 September 2017 
 
Version 4.1 Dated: 20 September2017, inclusive of administrative amendment 1 
 
5. Wolfe RA, Ashby VB, Milford El, et al: Comparison of mortality in all patients on dialysis, 
patients on dialysis awaiting transplantation and recipients of a first cadaveric transplant. 
N Engl J Med 1999;341:1725– 1730. 
6. Meier-Kriesche H., et al., Effect of Waiting Time on Renal Transplant Outcome, Kidney 
International (2000) 58, 1311–1317 
7. OPTN Final Rule §121.8 Allocation of organs, 64 FR 56659, Oct. 20, 1999, as amended 
at 64 FR 71626, Dec. 21, 1999 
8. Kucirka LM, Singer AL, Ros RL, Montgomery RA, Dagher NN, Segev DL, 
Underutilization of hepatitis C-positive kidneys for hepatitis C-positive recipients, Am J 
Transplant. 2010 May; 10(5):1238-46. 
9. Morales J.M., et al., Long-Term Experience with Kidney Transplantation From Hepatitis 
C-Positive Donors Into Hepatitis C-Positive Recipients, American J Transplant. 2010 
OCT; 10(11):2453-2462. 
10. Kucirka L.M., Singer A.L., Ros R.L., Montgomery R.A., Dagher N.N., Segev D.L., 
Underutilization of Hepatitis C-positive Kidneys for Hepatitis C-positive Recipients, Am J 
Transplant. 2010 May; 10(5):1238-46. 
11. Terrault N.A. and Stock P.G., Management of Hepatitis C in Kidney Transplant Patients: 
On the Cusp of Change, Am J of Transplantation. 2014; 14: 1955-1957. 
12. Fontana R.J. et al.,Sofosbuvir and Daclatasvir Combination Therapy in a Liver Transplant 
Recipient With Severe Recurrent Cholestatic Hepatitis C, Am J of Transplantation 2013; 
13: 1601-1605. Case Report. 
13. Fabrizi F. et al., Hepatitis C Virus Antibody Status and Survival After Renal 
Transplantation: Meta-Analysis of Observational Studies, Am J Transplant, 2005 
Jun;5(6):1452-61. 
14. Cruzado J.M., Carrera M., Torras J., Grinyo J.M., Hepatitis C Virus Infection and De Novo 
Glomerular Lesions in Renal Allografts, Am J Transplant. 2001 Jul;1(2):171-8. 
15. Funaoka M. et al., Fulminant Hepatitis C caused by hepatitis C virus during treatment for 
multiple sclerosis. J Gastroenterol. 1996; 31 (1): 119 – 22. 
16. Foster G, Suddle A. Treatment of HCV infection with pegylated interferons. Current 
Hepatitis Reports [serial online]. 2005;(2):49. Available from: Academic OneFile, 
Ipswich, MA. Accessed November 6, 2015. 
17. Sharfuddin A, Taber T, Mujtaba M, Yaqub M, Mishler D, Kwo P, Vuppalanchi R. 
Treatment of Hepatitis C Virus in Kidney Transplant Recipients With Direct Acting Anti-
Viral Agents: Early Results in 12 Cases [abstract]. Am J Transplant. 2015; 15 (suppl 3). 
18. Avik Majumdar • Matthew T. Kitson • Stuart K. Roberts. Treatment of Hepatitis C in 
Patients with Cirrhosis: Remaining Challenges for Direct-Acting Antiviral Therapy. 
Current Opinion Drugs (2015) 75: 823-834 
19. Roth D, Nelson DR, Bruchfeld A, et al. Grazoprevir plus elbasvir in treatment-naive and 
treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 
chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet 
2015;386:1537-45. 
20. Rao PS, Schaubel DE, Guidinger MD, et al. A comprehensive risk quantificaiotn score for 
deceased donor kidneys: the kidney donor risk index. Transplantation 2009;88:231-6 

Protocol: 2016P002051 
Compound: Elbasvir-grazoprevir                                                                                                            Final 
Raymond Chung, MD                                                                              Amendment 3: 20 September 2017 
 
Version 4.1 Dated: 20 September2017, inclusive of administrative amendment 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Protocol: 2016P002051 
Compound: Elbasvir-grazoprevir                                                                                                            Final 
Raymond Chung, MD                                                                              Amendment 3: 20 September 2017 
 
Version 4.1 Dated: 20 September2017, inclusive of administrative amendment 1 
 
Appendix 1: Study Assessments (Schedule of Events) 
  
Screening  
On treatment assessments 
  
  
  
  
  
  
Post Treatment Assessments 
  
Screening 
Visit 1 
Screening 
Visit 2 
Baseline 
Day 
1 
Day 
3 
Day 
7 
Week 
2 
Week 
4 
Week 
6 
Week 
8 
Week 
10 
Week 
12 
Week 
13 
Week 
16 
PT + 
4 
PT+12 
PT+24 
PT+40 (1 
year 
follow-
up) 
Clinical Assessments 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
Informed consent 
x 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
Determine Eligilibty 
x 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
Medical History 
x 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
Physical Exam 
x 
  
x 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
Height 
x 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
Weight 
x 
  
  
  
  
  
  
  
  
  
  
  
  
  
x 
  
  
x 
Vital Signs 
x 
  
  
  
  
  
  
  
  
  
  
  
  
  
x 
x 
x 
x 
Educational Session 
  
x 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
12-Lead EKG 
x 
  
  
x 
x 
x 
  
x 
  
  
  
x 
  
x 
  
  
  
  
AE's 
  
  
  
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
  
  
  
Concomitant Medications 
x 
  
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
Study Drug Dispensing 
  
  
x 
x 
x 
x 
  
x 
  
x 
  
x 
  
  
  
  
  
  
Quality of Life Questionnaires 
x 
  
  
  
  
  
  
  
  
x 
  
  
  
  
  
x 
  
x 
Phone Check in Prior to Transplant 
 
x 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Laboratory Assessments 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
Hematology (with differential) 
x 
  
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
Complete Metabolic Panel (inc. LFTs) 
x 
  
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
Coagulation (PT/INR, PTT) 
x 
  
x 
x 
x 
x 
x 
x 
x 
x 
HCV Ab 
x 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
HCV RNA 
  
  
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
HCV Genotyping 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
HIV Ab 
x 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
Urine Pregnancy* 
x 
  
  
  
  
  
  
x 
  
x 
  
x 
  
x 
x 
x 
x 
  
Urinalysis 
x 
  
x 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
Tacrolimus level 
  
  
  
  
  
  
  
  
  
  
  
  
x 
  
  
  
  
  
Kidney Function tests 
  
  
  
  
  
  
  
  
  
  
  
  
x 
  
  
  
  
  
Archive Plasma* (10ml) 
x 
  
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
Archive Serum* (10ml)  
x 
  
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
* Post transplant archive serum and plasma will only be collected if patients HBg is >9.5 

Protocol: 2016P002051 
Compound: Elbasvir-grazoprevir                                                                                                            Final 
Raymond Chung, MD                                                                              Amendment 3: 20 September 2017 
 
Version 4.1 Dated: 20 September2017, inclusive of administrative amendment 1